Use of iso-glycyrrhizic acid and salt thereof in treating allergic rhinitis

A technology for allergic rhinitis and isoglycyrrhizic acid, applied in the field of medicine

Active Publication Date: 2009-04-01
CHIA TAI TIANQING PHARMA GRP CO LTD
View PDF0 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no literature disclosing the application of glycyrrhizic acid, especially isoglycyrrhizic acid preparations, in the treatment of allergic rhinitis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of iso-glycyrrhizic acid and salt thereof in treating allergic rhinitis
  • Use of iso-glycyrrhizic acid and salt thereof in treating allergic rhinitis
  • Use of iso-glycyrrhizic acid and salt thereof in treating allergic rhinitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] 1. Experimental materials:

[0018] 1.1 Animals:

[0019] Wistar rats, male, 200-300 g. Provided by the Experimental Animal Center of the Academy of Military Medical Sciences of the Chinese People's Liberation Army, SCXK-(Army) 2002-001.

[0020] 1.2 Reagents:

[0021] ①. Calf serum albumin: provided by Nanjing Shengxing Company.

[0022] ② Complete Freund's adjuvant: provided by sigma company.

[0023] ③. Magnesium isoglycyrrhizinate (lummy): Provided by CTTQ company, and the required concentration was prepared with NS.

[0024] ④. Loratadine syrup: Provided by Schering-Plough, Belgium, 6ANNA56001, 200610, 1 mg / ml, prepared with NS at a suitable concentration for intragastric administration, with a dose of 1 mg / kg.

[0025] ⑤. Dexamethasone Sodium Phosphate Injection: Guizhou Huasheng Pharmaceutical Co., Ltd., 050103, prepared to a concentration of 5 mg / ml, and the intranasal administration dose of 10 μl / animal.

[0026] 1.3 Antigen suspension preparation:

[00...

Embodiment 2

[0040] Example 2 Magnesium Isoglycyrrhizinate Nasal Drops

[0041] prescription:

[0042]

[0043] Preparation:

[0044] 1) Solution preparation

[0045] Add magnesium isoglycyrrhizinate and sodium chloride into 4000ml of water for injection, stir to form a uniform suspension, adjust the pH value to 6.0 with NaOH, stir continuously to dissolve the main ingredient, add water for injection to a sufficient amount, and pass through a 0.22 μm filter membrane to obtain intermediate.

[0046] 2) Packing

[0047] After passing the inspection, the intermediates are aseptically divided into bottles according to the content of the intermediates and sealed with thermoplastic caps.

Embodiment 3

[0048] Example 3 Magnesium Isoglycyrrhizinate Nasal Drops

[0049] prescription:

[0050]

[0051]

[0052] Preparation:

[0053] 1) Solution preparation

[0054] Add magnesium isoglycyrrhizinate and sodium chloride into 4000ml of water for injection, stir to form a uniform suspension, adjust the pH value to 7.0 with ammonia water, stir continuously to dissolve the main ingredient, add water for injection to a sufficient amount, and pass through a 0.22 μm filter membrane to obtain intermediate.

[0055] 2) Packing

[0056] After passing the inspection, the intermediates are aseptically divided into bottles according to the content of the intermediates and sealed with thermoplastic caps.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to application of iso-glycyrrhizic acid or salt in a drug for remedying allergic rhinitis and the preparation of nasal drop and nasal spray preparation with the iso-glycyrrhizic acid or salt as an active component.

Description

Technical field: [0001] The invention relates to the field of medicine, in particular to the application of isoglycyrrhizic acid or its salt in treating allergic rhinitis and the suitable preparation form for treating allergic rhinitis. technical background: [0002] Allergic rhinitis (Allergic Rhinitis, AR) is one of the common diseases in otolaryngology-head and neck surgery. It is a type I allergic disease of the nasal mucosa mediated by IgE. Mucosa swelling is the main feature. It can be divided into perennial allergic rhinitis and seasonal allergic rhinitis, of which about 20% are seasonal, about 40% are perennial, and the remaining about 40% are the coexistence of the two. Although allergic rhinitis is not life-threatening, it seriously affects people's quality of life and increases the social burden. According to statistics, the United States spends about 6.3-7.9 billion dollars on this disease every year, and the global average incidence rate is 10%-25%. With the d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/704A61K9/08A61K9/12A61P11/02A61P37/08
Inventor 沈军徐宏江宋伟沈静
Owner CHIA TAI TIANQING PHARMA GRP CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap